{
  "ticker": "LLY",
  "target_date": "2024-12-26",
  "actual_date": "2024-12-26",
  "collected_at": "2025-12-08T11:11:58.114461",
  "price": {
    "open": 788.24,
    "high": 797.96,
    "low": 785.64,
    "close": 788.2605590820312,
    "volume": 1274200,
    "change_1d_pct": -0.19,
    "change_7d_pct": 1.94,
    "change_30d_pct": -2.86
  },
  "technicals": {
    "rsi_14": 37.38,
    "sma_20": 788.28,
    "sma_50": 807.31,
    "macd": -6.199,
    "macd_signal": -8.37,
    "macd_histogram": 2.171,
    "bb_upper": 827.53,
    "bb_lower": 749.03,
    "price_vs_sma20_pct": -0.0,
    "price_vs_sma50_pct": -2.36,
    "volume_ratio": 0.39
  },
  "fundamentals": {
    "market_cap": 891427684352,
    "pe_ratio": 48.720726,
    "forward_pe": 43.883057,
    "price_to_book": 37.439384,
    "price_to_sales": 15.002199,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.58,
    "pct_from_52w_low": 59.41
  },
  "macro": {
    "spy": {
      "price": 596.12,
      "change_1d_pct": 0.01,
      "change_7d_pct": -0.15
    },
    "vix": {
      "level": 14.73,
      "signal": "LOW_FEAR"
    },
    "treasury_10y": {
      "yield_pct": 4.58
    },
    "dollar_index": {
      "level": 108.13
    },
    "gold": {
      "price": 2638.8
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Healthcare: Why the sector underperformed in 2024",
      "source": "Yahoo",
      "datetime": 1735228380,
      "summary": "The healthcare sector (XLV) faced significant challenges in the markets throughout 2024, becoming the worst-performing S&P 500 (^GSPC) sector of the year. Yahoo Finance Senior Health Reporter Anjalee Khemlani analyzes the key market themes that influenced the sector this year and examines investor s",
      "url": "https://finnhub.io/api/news?id=c3da17b70c9a620e3f7353d5ef8a3740e69c98057f073b548babe5271da4bc9f"
    },
    {
      "headline": "Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.",
      "source": "Yahoo",
      "datetime": 1735226100,
      "summary": "Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for investors.",
      "url": "https://finnhub.io/api/news?id=e5432359ee63d97430231f0c3d809c1569d578a17f346071a103783aba39189d"
    },
    {
      "headline": "Jim Cramer Says Eli Lilly and Company (LLY)\u2019s \u2018Going To Win\u2019",
      "source": "Yahoo",
      "datetime": 1735225733,
      "summary": "We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. In his second appearance on Squawk on the Street after the Fed\u2019s interest rate cut, J",
      "url": "https://finnhub.io/api/news?id=6ff40b058278c4e45c7a126af81d84267efe7692c02997cc033dab8b8f9d95b7"
    },
    {
      "headline": "Elon Musk's Weight-Loss Secret Shakes Up Pharma Giants",
      "source": "Yahoo",
      "datetime": 1735223808,
      "summary": "Novo Nordisk and Eli Lilly face soaring demand--and stiff competition--as obesity drug market transforms healthcare and profits.",
      "url": "https://finnhub.io/api/news?id=5c81a3f7aac62781930daad994df73ebfa52e4a3f1a04825a6640e387c9f4c53"
    },
    {
      "headline": "Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?",
      "source": "Yahoo",
      "datetime": 1735218000,
      "summary": "Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk's (NYSE: NVO) stock crashed by 19% on Dec. 20, after the company reported results from a late-stage clinical trial that it framed as a success.  On Dec. 20, the bull thesis for Novo Nordisk stock took a m",
      "url": "https://finnhub.io/api/news?id=1c05fe8d7d4ee07a321063e083574d5a1dd2d808639df0b65316002c94e8fbf4"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470584.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000291/xslF345X05/wk-form4_1734470584.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470498.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000289/xslF345X05/wk-form4_1734470498.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470366.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000287/xslF345X05/wk-form4_1734470366.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470270.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000285/xslF345X05/wk-form4_1734470270.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470180.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000283/xslF345X05/wk-form4_1734470180.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}